Clinical Trial Update: Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated the safety and preliminary activity of a three-drug combination—decitabine, vorinostat, and cytarabine—in patients with relapsed or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Dacogen (decitabine)
• Zolinza (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia | Phase 1 | Status: COMPLETED